TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04735146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity.
Study: NCT05435417

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CBCT radiation
Description: CBCT scanning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CBCT radiation
Description: CBCT scanning
Study: NCT06047353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure (PAP) therapy
Description: Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
Study: NCT06159140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: In vivo MRI
Study: NCT05093296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: All participants will receive 50mg Naltrexone daily as oral tablet throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Pill
Description: All participants will receive 50mg Naltrexone daily as oral tablet throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
Study: NCT06545370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1 / Nurse-led patients' education
Description: nurse-led education through oral sessions, educational materials, and regular phone calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1 / Nurse-led patients' education
Description: nurse-led education through oral sessions, educational materials, and regular phone calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 2 / Nurse-led patients' & caregivers' education
Description: nurse-led education while caregivers also undergo training through oral sessions, phone calls, and appropriately designed educational materials
Study: NCT05580341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zerun HPV-9
Description: Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL ®9
Description: GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
Study: NCT04369157

Intervention type: PROCEDURE
Intervention: Elective surgery
Description: Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
Study: NCT06166108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane (TAP) block in Abdominal hysterectomy
Description: Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane (TAP) block in Abdominal hysterectomy
Description: Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
Study: NCT05630326

Intervention type: OTHER
Intervention: association
Description: comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

Intervention type: OTHER
Intervention: evaluation
Description: comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
Study: NCT04947917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SpotTM Tattoo Ink
Description: Ink injection
Study: NCT05167591

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug concentration measurement
Description: Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
Study: NCT05735535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral Agents
Description: two-drug one-pill once day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiviral Agents
Description: two-drug one-pill once day
Study: NCT04995861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block and IPACK block
Description: Peripheral nerve blocks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block and IPACK block
Description: Peripheral nerve blocks
Study: NCT04706130

Intervention type: DRUG
Group type: OTHER
Intervention: Primaquine
Description: After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites

Intervention type: DRUG
Group type: OTHER
Intervention: Primaquine
Description: After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites

Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate
Description: All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites

Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate
Description: All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites

Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate
Description: All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
Study: NCT06050551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uniportal VATS
Description: 1. elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~   (exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~2. thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~3. routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: uniportal VATS
Description: 1. elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~   (exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~2. thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~3. routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need.
Study: NCT06416696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration.
Study: NCT03992443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUSA-081
Description: Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
Study: NCT05450887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid Tablets（OCA）
Description: Obeticholic Acid：Once a day (QD) by mouth (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA：13\~15 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA：13\~15 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo：Once a day (QD) by mouth (PO).
Study: NCT06366035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoVE4MUM mobile application
Description: LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
Study: NCT04914390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT regimen
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
Study: NCT04985812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67484703
Description: Participants will receive JNJ-67484703.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo to JNJ-67484703.
Study: NCT06122142

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transfluthrin - delivery by paid study personnel
Description: Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfluthrin - delivery by voucher system
Description: Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfluthrin - delivery by village health teams
Description: Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
Study: NCT05930665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin
Description: Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
Study: NCT06142721

Intervention type: OTHER
Intervention: 3D Gait Analysis
Description: 3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated

Intervention type: OTHER
Intervention: 3D Gait Analysis
Description: 3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated

Intervention type: OTHER
Intervention: 3D Gait Analysis
Description: 3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated
Study: NCT04818190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory neurotization
Description: The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
Study: NCT05693285

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05217251

Intervention type: OTHER
Intervention: frontal alpha asymmetry in EEG
Description: frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.

Intervention type: OTHER
Intervention: frontal alpha asymmetry in EEG
Description: frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
Study: NCT05423600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BES + TS
Description: Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: BES+sham TS
Description: Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
Study: NCT06568237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56286
Description: TEV-56286 capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally
Study: NCT05019924

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Semaine
Description: The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
Study: NCT05077293

Intervention type: OTHER
Intervention: Best Practice Alert (BPA)
Description: A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.

Intervention type: OTHER
Intervention: In-Basket Message
Description: An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
Study: NCT06122090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost will be delivered with laser
Study: NCT06351722

Intervention type: DIAGNOSTIC_TEST
Intervention: Before non-surgical periodontal treatment
Description: Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.~Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR.
Study: NCT06122090

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline control will be delivered with laser
Study: NCT04703959

Intervention type: OTHER
Intervention: polysomnography
Description: polysomnography is already done for all patients
Study: NCT06120439

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PECS II combined with intercostal nerve blockade;
Description: The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with laryngeal mask
Description: The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
Study: NCT06076863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Care
Description: Management of Paxlovid e-visits per regional protocol
Study: NCT01311193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light therapy
Description: early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
Study: NCT05957783

Intervention type: OTHER
Intervention: Cerebral palsy Gait analysis technique
Description: Visual gait analysis in cerebral palsy new technique

Intervention type: OTHER
Intervention: Cerebral palsy Gait analysis technique
Description: Visual gait analysis in cerebral palsy new technique
Study: NCT06076863

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AFM Pool Care
Description: Management of Paxlovid e-visits per regional and local protocols
Study: NCT05957783

Intervention type: OTHER
Intervention: Cerebral palsy Gait analysis technique
Description: Visual gait analysis in cerebral palsy new technique
Study: NCT04328974

Intervention type: PROCEDURE
Intervention: lumbar CSF drainage
Description: We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
Study: NCT05398939

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test and skin evaluation
Description: The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
Study: NCT06541184

Intervention type: DRUG
Intervention: Ziconotide [Prialt]
Description: Intrathecal injection of ziconotide, using an internal pump, surgically inserted by a trained neurosurgeon or anesthesiologist, under general anesthesia.
Study: NCT05786417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Discretion
Description: Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Discretion
Description: Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
Study: NCT06539117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early feeding post caesarean section
Description: In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early feeding post caesarean section
Description: In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
Study: NCT06182644

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAPI PET/CT
Description: The same group of patients underwent FAPI PET/CT and FDG PET/CT examinations respectively
Study: NCT05786417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Selection of the specific BB and initial starting dose will be determined by the treating clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Description: Selection of the specific CCB and initial starting dose will be determined by the treating clinician.